¼¼°èÀÇ ÇǺ기 ½Ç¶õÆ® ½ÃÀå
Fibrin Sealants
»óǰÄÚµå : 1655473
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 92 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,260,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,780,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÇǺ기 ½Ç¶õÆ® ½ÃÀåÀº 2030³â±îÁö 16¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 11¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÇǺ기 ½Ç¶õÆ® ½ÃÀåÀº 2024-2030³â¿¡ CAGR 6.1%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 16¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ÇǺ기 ½Ç¶õÆ®¾×Àº CAGR 6.4%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 12¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇǺ기 ½Ç¶õÆ® ÆÐÄ¡ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 5.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 9,310¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÇǺ기 ½Ç¶õÆ® ½ÃÀåÀº 2024³â¿¡ 2¾ï 9,310¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀ» 9.1%·Î °ßÀÎÇϸç 2030³â±îÁö 3¾ï 6,410¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.3%¿Í 5.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÇǺ기 ½Ç¶õÆ® ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÇǺ기 ½Ç¶õÆ®´Â ¹«¾ùÀ̸ç, ¿Ö ÀÇ·á ¿ëµµ¿¡ ÇʼöÀûÀΰ¡?

ÇǺ기 ½Ç¶õÆ®´Â »óó Ä¡À¯¿Í Á¶Á÷ ȸº¹À» ÃËÁøÇϱâ À§ÇØ ´Ù¾çÇÑ ÀÇ·á¿ëÀ¸·Î »ç¿ëµÇ´Â »ý¹°ÇÐÀû Á¢ÂøÁ¦ÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. ÇǺ긮³ë°Õ°ú Æ®·ÒºóÀ¸·Î ±¸¼ºµÈ ÀÌ ½Ç¶õÆ®´Â Ç÷¾× ÀÀ°í °úÁ¤ÀÇ ¸¶Áö¸· ´Ü°è¸¦ ¸ð¹æÇÏ¿© »óó¸¦ È¿°úÀûÀ¸·Î ¹ÐºÀÇϰí ÁöÇ÷À» ÃËÁøÇÏ´Â ÇǺ기 µ¢¾î¸®ÀÇ Çü¼ºÀ» ÃËÁøÇÕ´Ï´Ù. ÇǺ기 ½Ç¶õÆ®´Â ÀÏ¹Ý ¿Ü°ú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ½ÉÇ÷°ü¿Ü°ú µî ´Ù¾çÇÑ ¿Ü°ú¼ö¼ú¿¡ »ç¿ëµË´Ï´Ù. Á¶Á÷ Ç¥¸é¿¡ Á¢ÂøÇϰí ÃâÇ÷À» ¾ïÁ¦Çϸç Ä¡À¯¸¦ ÃËÁøÇÏ´Â ´É·ÂÀº ¿Ü°ú ÀÇ»ç¿Í ÀÇ·á Àü¹®°¡¿¡°Ô ±ÍÁßÇÑ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÀÇ·á ÇöÀå¿¡¼­ ÇǺ기 ½Ç¶õÆ®ÀÇ Á߿伺Àº Á¢Âø·Â¿¡¸¸ ±¹ÇѵÇÁö ¾Ê½À´Ï´Ù. ÇǺ기 ½Ç¶õÆ®´Â ÃâÇ÷À» °ü¸®Çϰí Á¶Á÷ Ä¡À¯¸¦ ÃËÁøÇÏ´Â ÃÖ¼Ò Ä§½ÀÀû ¼Ö·ç¼ÇÀ» Á¦°øÇÏ¿© ƯÁ¤ ½Ã¼ú¿¡¼­ ±âÁ¸ ºÀÇջ糪 ½ºÅ×ÀÌÇÃÀÇ Çʿ伺À» ÁÙ¿©ÁÝ´Ï´Ù. ¶ÇÇÑ ÇǺ기 ½Ç¶õÆ®´Â Ç×»ýÁ¦³ª ¼ºÀåÀÎÀÚ µîÀÇ Ä¡·áÁ¦¸¦ »óó ºÎÀ§¿¡ Á÷Á¢ Àü´ÞÇÏ¿© Ä¡·á È¿°ú¸¦ ´õ¿í ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ÷´Ü »óó Ä¡·á ¹× ¼ö¼ú ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ȯÀÚ °á°ú¿Í ¼ö¼ú È¿À²À» Çâ»ó½ÃŰ´Â ÇǺ기 ½Ç¶õÆ®ÀÇ ¿ªÇÒÀÌ Á¡Á¡ ´õ ¸¹ÀÌ Àνĵǰí ÀÖ½À´Ï´Ù.

ÇǺ기 ½Ç¶õÆ®ÀÇ ÁÖ¿ä ¿ëµµ¿Í ÇコÄÉ¾î ¿ä±¸´Â ¹«¾ùÀΰ¡?

ÇǺ기 ½Ç¶õÆ®´Â ´Ù¾çÇÑ ÀÇ·á ºÐ¾ß¿¡¼­ ÀÇ·áÁø°ú ȯÀÚÀÇ Çʿ信 µû¶ó Æø³Ð°Ô Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÏ¹Ý ¿Ü°ú¿¡¼­ ÇǺ기 ½Ç¶õÆ®´Â °£ ÀýÁ¦¼ú, À§ ÀýÁ¦¼ú, ´ëÀå ÀýÁ¦¼ú°ú °°Àº ¼ö¼ú Áß ÃâÇ÷À» Á¶ÀýÇϱâ À§ÇØ ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù. ºü¸¥ ÁöÇ÷ÀÌ °¡´ÉÇϹǷΠÃâÇ÷·®À» ÁÙÀ̰í ÇÕº´Áõ À§ÇèÀ» ÁÙÀÌ¸ç ±Ã±ØÀûÀ¸·Î ¼ö¼ú °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇǺ기 ½Ç¶õÆ®¸¦ ÀÌ·¯ÇÑ ¿ëµµ·Î »ç¿ëÇϸé ȸº¹ ½Ã°£À» ¿¬ÀåÇÏ°í ¼ö¼ú ÈÄ ÅëÁõÀ» ÃÖ¼ÒÈ­ÇÏ¿© ȯÀÚ¿Í ÀÇ·á ½Ã¼³ ¸ðµÎ¿¡ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

Á¤Çü¿Ü°ú¼ö¼ú¿¡¼­ ÇǺ기 ½Ç¶õÆ®´Â Á¶Á÷ Ä¡À¯¸¦ Áö¿øÇϰí Àΰø°üÀý ġȯ¼ú, ÀÎ´ë ¼öº¹¼ú, °ñÀý °íÁ¤¼ú°ú °°Àº ¼ö¼ú ÈÄ ÇÕº´Áõ À§ÇèÀ» ÁÙÀ̱â À§ÇØ »ç¿ëµË´Ï´Ù. ÇǺ기 ½Ç¶õÆ®´Â Á¶Á÷ Á¢ÂøÀ» ÃËÁøÇϰí Ä¡À¯ °úÁ¤À» °³¼±ÇÏ¿© ȯÀÚÀÇ Á¶±â ȸº¹°ú ±â´ÉÀû °á°ú¸¦ °³¼±ÇÏ´Â µ¥ ±â¿©ÇÕ´Ï´Ù. ¿Ü°ú ÀÇ»çµéÀÌ ¼ö¼ú °á°ú¸¦ ÃÖÀûÈ­Çϱâ À§ÇÑ È¿°úÀûÀÎ ¼Ö·ç¼ÇÀ» ãÀ¸¸é¼­ ±Ù°ñ°Ý°è ¼Õ»ó °ü¸®¿¡ ´ëÇÑ Àû¿ëÀÌ Á¡Á¡ ´õ º¸ÆíÈ­µÇ°í ÀÖ½À´Ï´Ù.

³ú½Å°æ¿Ü°úµµ ÇǺ기 ½Ç¶õÆ®°¡ Àα⸦ ²ø°í ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù. ÀÌ Á¦Ç°µéÀº ÃâÇ÷ Á¶ÀýÀÌ Áß¿äÇÑ µÎ°³°ñ ¹× ôÃß ¼ö¼ú Áß ÃâÇ÷ °ü¸®¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÇǺ기 ½Ç¶õÆ®ÀÇ »ýü ÀûÇÕ¼º°ú Á¢Âø·ÂÀº ¼¶¼¼ÇÑ ¼ö¼ú ȯ°æ¿¡¼­ »ç¿ëÇϱ⿡ ÀÌ»óÀûÀ̸ç, ÁÖº¯ Á¶Á÷À» ¼Õ»ó½ÃŰÁö ¾Ê°í ÃâÇ÷À» È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½Å°æ¿Ü°ú¼ö¼ú ±â¼úÀÌ ¹ßÀüÇÔ¿¡ µû¶ó ÇǺ기 ½Ç¶õÆ®ÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÇǺ기 ½Ç¶õÆ®´Â ½ÉÇ÷°ü ¼ö¼ú, ƯÈ÷ ½ÉÀå ¿ìȸ¼ú°ú ÆÇ¸· ġȯ¼ú¿¡µµ »ç¿ëµË´Ï´Ù. ÇǺ기 ½Ç¶õÆ®´Â ±âÁ¸ ºÀÇÕÀÌ ¾î·Á¿î ºÎÀ§¿¡¼­ È¿°úÀûÀÎ ÁöÇ÷À» ÅëÇØ ¼ö¼úÀÇ Á¤È®¼ºÀ» ³ôÀÌ°í ¼ö¼ú ÈÄ ÃâÇ÷ÀÇ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ÃÖ¼Òħ½ÀÀû ½ÉÇ÷°ü ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó »óó ºÀÇÕ°ú Ä¡À¯¸¦ È¿°úÀûÀ¸·Î ÃËÁøÇÏ´Â ÇǺ기 ½Ç¶õÆ®¿Í °°Àº Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ÇǺ기 ½Ç¶õÆ®´Â »óó Ä¡·á ¹× Á¶Á÷ °øÇÐ µî »õ·Î¿î ¿ëµµ¿¡¼­µµ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ÇǺ기 ½Ç¶õÆ®´Â Á¶Á÷ Àç»ýÀ» À§ÇÑ Áö¿ø ȯ°æÀ» Á¦°øÇÔÀ¸·Î½á Ä¡·á°¡ ¾î·Á¿î »óóÀÇ Ä¡À¯¸¦ ÃËÁøÇÒ ¼ö ÀÖÀ¸¹Ç·Î ¸¸¼º »óó °ü¸®¿¡ ´ëÇÑ Àû¿ëÀÌ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ¿¬±¸°¡ ÁøÇàµÊ¿¡ µû¶ó »õ·Î¿î ¿ëµµ°¡ ¹ß°ßµÊ¿¡ µû¶ó ÇコÄÉ¾î »ê¾÷¿¡¼­ ÇǺ기 ½Ç¶õÆ®ÀÇ °¡´É¼ºÀº ´õ¿í È®´ëµÇ¾î ´õ ±¤¹üÀ§ÇÑ ÀÇ·á ¼ö¿ä¸¦ ÃæÁ·½Ãų ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ¼¶À¯¼Ò ½Ç¶õÆ® ½ÃÀå¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº Á¦Ç° Á¦ÇüÀÇ °³¼±, Àû¿ë ±â¼úÀÇ Çâ»ó, ÀÓ»ó »ç¿ëÀÇ È®´ë·Î ÀÎÇØ ÇǺ기 ½Ç¶õÆ® ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÁÖ¸ñÇÒ ¸¸ÇÑ °³¹ß Áß Çϳª´Â ÇǺ기 ½Ç¶õÆ® Á¦Á¦ÀÇ ±â¼ú Çõ½ÅÀ¸·Î, ¼º´É°ú »ç¿ë ÆíÀǼºÀ» Çâ»ó½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº Á¡µµ¿Í À¯µ¿¼ºÀ» ÃÖÀûÈ­ÇÑ ÇǺ기 ½Ç¶õÆ®¸¦ °³¹ßÇÏ¿© º¸´Ù ½±°Ô µµÆ÷Çϰí Á¶Á÷ Ç¥¸é¿¡ ´õ Àß Á¢ÂøÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î ÀÎÇØ ÇǺ기 ½Ç¶õÆ®´Â ¿Ü°ú ÀÇ»çµéÀÌ ´õ ½±°Ô »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, ´Ù¾çÇÑ ¼ö¼ú¿¡ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ »õ·Î¿î Àü´Þ ½Ã½ºÅÛÀÇ ¿¬±¸·Î ÀÎÇØ ÇǺ기 ½Ç¶õÆ®ÀÇ ÀáÀçÀû ¿ëµµ°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ½ºÇÁ·¹ÀÌ ¾îÇø®ÄÉÀÌÅÍ ¹× ±âŸ ÷´Ü Àü´Þ ¹æ¹ýÀÇ °³¹ß·Î ÇǺ기 ½Ç¶õÆ®ÀÇ Á¤È®Çϰí Á¤È®ÇÑ Àû¿ëÀÌ °¡´ÉÇØÁ® ´Ù¾çÇÑ ÀÓ»ó ÇöÀå¿¡¼­ÀÇ È¿´ÉÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àü´Þ Çõ½ÅÀ¸·Î ÀÇ·áÁøÀº º¸´Ù ´Ù¾çÇÑ ½Ã¼ú¿¡ ¼¶À¯¼Ò ½Ç¶õÆ®¸¦ »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾î ÃÖÀûÀÇ ¼º´É°ú °á°ú¸¦ º¸ÀåÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

ÇǺ기 ½Ç¶õÆ® Á¦Á¦¿¡ »ýü ÀûÇÕ¼º ¹× »ý¹°ÇÐÀû Ȱ¼º ¼ººÐÀÇ ÅëÇÕÀº ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¶Ç ´Ù¸¥ Ãß¼¼ÀÔ´Ï´Ù. Á¦Á¶¾÷üµéÀº ¼ºÀåÀÎÀÚ, Ç×±ÕÁ¦ ¹× ±âŸ Ä¡·á¿ë ÷°¡Á¦¸¦ ÇǺ기 ½Ç¶õÆ®¿¡ ÅëÇÕÇÏ¿© Ä¡À¯·ÂÀ» ³ôÀ̱â À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Á¶Á÷ Àç»ýÀ» ÃËÁøÇÏ°í °¨¿° À§ÇèÀ» ÁÙÀÓÀ¸·Î½á ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â´É °­È­ÀÇ ÀÌÁ¡ÀÌ ¹àÇôÁö¸é¼­ ´Ù±â´É¼º ÇǺ기 ½Ç¶õÆ®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ÃÖ¼Òħ½À ¼ö¼ú ±â¼úÀÇ ¹ßÀüÀº ÇǺ기 ½Ç¶õÆ® ½ÃÀå¿¡µµ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¿Ü°ú ÀÇ»çµéÀÌ º¸´Ù ÃÖ¼Ò Ä§½ÀÀûÀÎ ¼ö¼ú¹ýÀ» äÅÃÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ¼ö¼ú¹ýÀ» À§ÇÑ È¿°úÀûÀÎ »óó ºÀÇÕ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇǺ기 ½Ç¶õÆ®´Â ±âÁ¸ÀÇ ºÀÇջ縦 »ç¿ëÇÏÁö ¾Ê°í ÁöÇ÷°ú Ä¡À¯¸¦ ÃËÁøÇϱâ À§ÇÑ ÀûÀýÇÑ ¿É¼ÇÀ» Á¦°øÇϹǷΠÃÖ¼Ò Ä§½À ¼ö¼ú¿¡¼­ ¼±È£µÇ°í ÀÖ½À´Ï´Ù.

ÇǺ기 ½Ç¶õÆ® ½ÃÀåÀº ȯÀÚ ¾ÈÀü°ú ±ÔÁ¦ Áؼö¿¡ ´ëÇÑ °ü½Éµµ Çõ½ÅÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº Á¦Ç°ÀÌ ÃÖ°íÀÇ ¾ÈÀü¼º°ú À¯È¿¼º ±âÁØÀ» ÃæÁ·ÇÒ ¼ö ÀÖµµ·Ï ¿¬±¸¿Í ½ÃÇè¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÓ»óÀû È¿°ú¿Í ¾ÈÀü¼ºÀÌ ÀÔÁõµÈ ÇǺ기 ½Ç¶õÆ® °³¹ß¿¡ ÁýÁßÇÏ´Â °ÍÀº ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿Í ±ÔÁ¦ ´ç±¹ÀÇ ÀÎÁ¤À» ¹Þ±â À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ç°Áú°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ³ë·ÂÀº ÀÇ·á°è¿¡¼­ ÇǺ기 ½Ç¶õÆ®ÀÇ ÀÎÁöµµ¸¦ ³ôÀÌ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ÇǺ기 ½Ç¶õÆ® ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

ÇǺ기 ½Ç¶õÆ® ½ÃÀåÀÇ ¼ºÀåÀº ¿Ü°ú¼ö¼ú Áõ°¡, ÷´Ü »óó °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¼ö¼ú ÈÄ ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇÑ ³ë·Â µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â Àü ¼¼°è ¼ö¼ú °Ç¼ö Áõ°¡ÀÔ´Ï´Ù. ÇコÄÉ¾î »ê¾÷ÀÌ Áö¼ÓÀûÀ¸·Î ¼ºÀåÇÔ¿¡ µû¶ó È¿°úÀûÀÎ ÁöÇ÷Á¦ ¹× »óó ºÀÇÕ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇǺ기 ½Ç¶õÆ®´Â ÃâÇ÷À» ¾ïÁ¦Çϰí Ä¡À¯¸¦ ÃËÁøÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ ¿É¼ÇÀ» Á¦°øÇϸç, ´Ù¾çÇÑ ¿Ü°úÀû Àü¹® ºÐ¾ß¿¡¼­ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

÷´Ü »óó Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡µµ ½ÃÀå ¼ºÀåÀÇ Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. ¸¸¼º »óó, ¿åâ, ¼ö¼ú ºÎÀ§ °¨¿° µîÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â »óó Ä¡À¯¸¦ ÃËÁøÇϰí ÇÕº´ÁõÀ» ÁÙÀÏ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ Á¢±Ù¹ýÀ» ã°í ÀÖ½À´Ï´Ù. Á¶Á÷ ȸº¹À» µ½°í °¨¿° À§ÇèÀ» ÁÙÀÌ´Â ±â´ÉÀ» °¡Áø ÇǺ기 ½Ç¶õÆ®´Â »óó °ü¸® ºÐ¾ß¿¡¼­ Á¡Á¡ ´õ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ȯÀÚ ¾ÈÀü°ú ÀÓ»ó °á°ú °³¼±¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ È¿°úÀûÀÎ »óó °ü¸® Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¼ö¼ú ÈÄ ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­Çϰí ȸº¹ ½Ã°£À» ¿¬ÀåÇÏ´Â µ¥ ÁßÁ¡À» µÎ°í ÀÖ´Â °Íµµ ÇǺ기 ½Ç¶õÆ® ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº ÇǺ기 ½Ç¶õÆ®¸¦ »ç¿ëÇϸé ÃâÇ÷À» ÁÙÀ̰í Ä¡À¯¸¦ ÃËÁøÇϸç Ãß°¡ °³ÀÔÀÇ Çʿ伺À» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ´Ù´Â ÀÌÁ¡À» ÀνÄÇϰí ÀÖ½À´Ï´Ù. º´¿ø°ú ¼ö¼ú¼¾ÅͰ¡ ȯÀÚ °á°ú¿Í È¿À²¼ºÀ» ¿ì¼±½ÃÇÔ¿¡ µû¶ó ¿Ü°ú Áø·á¿¡¼­ ÇǺ기 ½Ç¶õÆ®ÀÇ Ã¤ÅÃÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ¼ö¼ú ±â¼ú°ú ±â¼úÀÇ ¹ßÀüÀ¸·Î ÇǺ기 ½Ç¶õÆ®¸¦ ÀÏ»óÀûÀÎ ¼ö¼ú¿¡ ½±°Ô ÅëÇÕÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÃÖ¼Ò Ä§½À ¼ö¼úÀÌ ´ëÁßÈ­µÊ¿¡ µû¶ó ÀÌ·¯ÇÑ ±â¼ú¿¡ ´ëÀÀÇÏ´Â È¿°úÀûÀÎ »óó ºÀÇÕ ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Á¡Á¡ ´õ Ä¿Áö°í ÀÖ½À´Ï´Ù. ÇǺ기 ½Ç¶õÆ®´Â ±âÁ¸ÀÇ ºÀÇջ縦 »ç¿ëÇÏÁö ¾Ê°íµµ ÁöÇ÷°ú Ä¡À¯¸¦ ÃËÁøÇÒ ¼ö ÀÖ´Â ÀûÀýÇÑ ¿É¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ´Ù¾çÇÑ ¿Ü°úÀû Àü¹® ºÐ¾ß¿¡¼­ »ç¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î ´Ù¾çÇÑ ¿ëµµ¿¡¼­ ¼¶À¯¼Ò ½Ç¶õÆ®ÀÇ È¿´ÉÀ» Á¶»çÇÏ´Â ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸ ¹× ÀÓ»ó ¿¬±¸°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ¼ö¼ú¿¡¼­ ÇǺ기 ½Ç¶õÆ®ÀÇ ÀÌÁ¡¿¡ ´ëÇÑ »õ·Î¿î Áõ°Å°¡ µîÀåÇÔ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº ÀÌ·¯ÇÑ Á¦Ç°À» Áø·á¿¡ µµÀÔÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ÇǺ기 ½Ç¶õÆ® »ç¿ëÀ» ÁöÁöÇÏ´Â ÀÓ»ó µ¥ÀÌÅͰ¡ È®´ëµÊ¿¡ µû¶ó ÀÇ·á°è¿¡¼­ ÇǺ기 ½Ç¶õÆ®ÀÇ ¼ö¿ë°ú »ç¿ëÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

°á·ÐÀûÀ¸·Î, ÇǺ기 ½Ç¶õÆ® ½ÃÀåÀº ¿Ü°ú¼ö¼ú Áõ°¡, ÷´Ü »óó °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¼ö¼ú ÈÄ ÇÕº´Áõ ÃÖ¼ÒÈ­¿¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇØ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦Ç° ó¹æ ¹× Àü´Þ ¹æ¹ýÀÇ ±â¼ú ¹ßÀüÀº ½ÃÀå ÀáÀç·ÂÀ» ´õ¿í ³ôÀÏ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀÌ È¯ÀÚÀÇ ¾ÈÀü°ú È¿°úÀûÀÎ »óó °ü¸®¸¦ ÃÖ¿ì¼± °úÁ¦·Î »ï°í ÀÖ´Â °¡¿îµ¥, ÇǺ기 ½Ç¶õÆ®¿¡ ´ëÇÑ ¼ö¿ä´Â ÇâÈÄ ¼ö³â°£ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

À¯Çü(¾×ü, ÆÐÄ¡);&¿ëµµ(½ÉÇ÷°ü¿Ü°ú, Á¤Çü¿Ü°ú, ÀϹݿܰú, À̽Ŀܰú, ±âŸ ¿ëµµ);&ÃÖÁ¾ ¿ëµµ(º´¿ø, Àü¹®Å¬¸®´Ð, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 36»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Fibrin Sealants Market to Reach US$1.6 Billion by 2030

The global market for Fibrin Sealants estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Fibrin Sealant Liquid, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Fibrin Sealant Patches segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$293.1 Million While China is Forecast to Grow at 9.1% CAGR

The Fibrin Sealants market in the U.S. is estimated at US$293.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$364.1 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Fibrin Sealants Market – Key Trends & Drivers Summarized

What Are Fibrin Sealants, And Why Are They Essential in Medical Applications?

Fibrin sealants are a type of biological adhesive used in various medical applications to promote wound healing and tissue repair. Composed of fibrinogen and thrombin, these sealants mimic the final stages of the blood coagulation process, facilitating the formation of a fibrin clot that effectively seals wounds and enhances hemostasis. Fibrin sealants are used in a wide range of surgical procedures, including general surgery, orthopedics, neurosurgery, and cardiovascular surgery. Their ability to adhere to tissue surfaces, control bleeding, and accelerate healing makes them a valuable tool for surgeons and healthcare professionals.

The significance of fibrin sealants in medical practice extends beyond their adhesive properties. They provide a minimally invasive solution for managing bleeding and promoting tissue healing, reducing the need for traditional sutures and staples in certain procedures. Additionally, fibrin sealants can deliver therapeutic agents, such as antibiotics or growth factors, directly to the wound site, further enhancing their effectiveness. As the demand for advanced wound care and surgical solutions continues to rise, the role of fibrin sealants in improving patient outcomes and surgical efficiency is increasingly recognized.

What Are the Main Applications of Fibrin Sealants, And How Do They Cater to Healthcare Needs?

Fibrin sealants have a wide range of applications across various medical fields, catering to the specific needs of healthcare providers and patients. In general surgery, fibrin sealants are commonly used to control bleeding during procedures such as liver resections, gastric surgeries, and colorectal surgeries. Their ability to provide rapid hemostasis helps reduce blood loss and the risk of complications, ultimately improving surgical outcomes. The use of fibrin sealants in these applications also enhances recovery times and minimizes postoperative pain, benefiting both patients and healthcare facilities.

In orthopedic surgery, fibrin sealants are employed to support tissue healing and reduce the risk of complications following procedures such as joint replacements, ligament repairs, and fracture fixations. By promoting the adhesion of tissues and enhancing the healing process, fibrin sealants contribute to faster recovery and improved functional outcomes for patients. Their application in managing musculoskeletal injuries is becoming increasingly common as surgeons seek effective solutions to optimize surgical results.

Neurosurgery is another area where fibrin sealants are gaining traction. They are used to manage bleeding during cranial and spinal procedures, where controlling hemorrhage is critical. The biocompatibility and adhesive properties of fibrin sealants make them ideal for use in delicate surgical environments, ensuring that bleeding is effectively managed without compromising surrounding tissues. As advancements in neurosurgical techniques continue, the adoption of fibrin sealants is expected to increase.

Fibrin sealants are also used in cardiovascular surgery, particularly in procedures involving cardiac bypass and valve replacement. They provide effective hemostasis in areas where traditional sutures may be challenging to apply, enhancing surgical precision and reducing the risk of postoperative bleeding. The growing demand for minimally invasive cardiovascular procedures is further driving the need for innovative solutions like fibrin sealants that promote effective wound closure and healing.

Furthermore, fibrin sealants are being explored in emerging applications, such as wound care and tissue engineering. Their use in chronic wound management is gaining attention, as they can enhance healing in difficult-to-treat wounds by providing a supportive environment for tissue regeneration. As research continues to uncover new applications, the potential for fibrin sealants in the healthcare industry will likely expand, catering to a broader range of medical needs.

How Are Technological Advancements Impacting the Fibrin Sealants Market?

Technological advancements are significantly influencing the fibrin sealants market by improving product formulations, enhancing application techniques, and expanding their clinical use. One notable development is the innovation in fibrin sealant formulations, which aim to enhance their performance and usability. Manufacturers are focusing on creating fibrin sealants with optimized viscosity and flow characteristics, enabling easier application and improved adhesion to tissue surfaces. These advancements make fibrin sealants more user-friendly for surgeons, contributing to their growing adoption in various surgical procedures.

Additionally, research into novel delivery systems is expanding the potential applications of fibrin sealants. The development of spray applicators and other advanced delivery methods allows for precise and targeted application of fibrin sealants, improving their effectiveness in diverse clinical settings. These delivery innovations enable healthcare providers to use fibrin sealants in a broader range of procedures, ensuring optimal performance and outcomes.

The integration of biocompatible and bioactive components into fibrin sealant formulations is another trend impacting the market. Manufacturers are exploring the incorporation of growth factors, antimicrobial agents, and other therapeutic additives into fibrin sealants to enhance their healing properties. These advancements are aimed at improving patient outcomes by promoting tissue regeneration and reducing the risk of infection. As research continues to uncover the benefits of these enhancements, the demand for multifunctional fibrin sealants is expected to grow.

Moreover, the rise of minimally invasive surgical techniques is influencing the fibrin sealants market. As surgeons increasingly adopt less invasive approaches to procedures, the need for effective wound closure solutions that align with these techniques is rising. Fibrin sealants provide a suitable option for achieving hemostasis and promoting healing without the need for traditional sutures, making them a preferred choice in minimally invasive surgeries.

The emphasis on patient safety and regulatory compliance is also driving innovation in the fibrin sealants market. Manufacturers are investing in research and testing to ensure that their products meet the highest safety and efficacy standards. The focus on developing fibrin sealants with proven clinical benefits and safety profiles is essential for gaining acceptance among healthcare providers and regulatory bodies. This commitment to quality and safety is expected to enhance the reputation of fibrin sealants in the medical community.

What Is Driving the Growth in the Fibrin Sealants Market?

The growth in the fibrin sealants market is driven by several key factors, including increasing surgical procedures, rising demand for advanced wound care solutions, and a focus on minimizing postoperative complications. One of the primary drivers is the growing number of surgical procedures performed globally. As the healthcare industry continues to expand, the demand for effective hemostatic agents and wound closure solutions is increasing. Fibrin sealants provide an effective option for controlling bleeding and promoting healing, making them essential in various surgical specialties.

The rising demand for advanced wound care solutions is another significant factor contributing to market growth. With an increasing prevalence of chronic wounds, pressure ulcers, and surgical site infections, healthcare providers are seeking innovative approaches to enhance wound healing and reduce complications. Fibrin sealants, with their ability to support tissue repair and reduce infection risks, are becoming increasingly popular in wound management. The ongoing emphasis on patient safety and improved clinical outcomes is further driving the demand for effective wound care products.

Additionally, the focus on minimizing postoperative complications and enhancing recovery times is influencing the fibrin sealants market. Healthcare providers are recognizing the benefits of using fibrin sealants in reducing bleeding, promoting healing, and minimizing the need for additional interventions. As hospitals and surgical centers prioritize patient outcomes and efficiency, the adoption of fibrin sealants in surgical practice is expected to grow.

Moreover, advancements in surgical techniques and technology are facilitating the integration of fibrin sealants into routine surgical practice. As minimally invasive procedures gain popularity, the need for effective wound closure solutions that align with these techniques becomes increasingly important. Fibrin sealants provide a suitable option for achieving hemostasis and promoting healing without the need for traditional sutures, contributing to their growing use in various surgical specialties.

Finally, ongoing research and clinical studies investigating the efficacy of fibrin sealants in different applications are driving market growth. As new evidence emerges regarding the benefits of fibrin sealants in various surgical procedures, healthcare providers are likely to incorporate these products into their practice. The expanding body of clinical data supporting the use of fibrin sealants will enhance their acceptance and utilization in the medical community.

In conclusion, the fibrin sealants market is poised for significant growth driven by increasing surgical procedures, rising demand for advanced wound care solutions, and a focus on minimizing postoperative complications. Technological advancements in product formulations and delivery methods will further enhance the market's potential. As healthcare providers continue to prioritize patient safety and effective wound management, the demand for fibrin sealants is expected to flourish in the coming years.

SCOPE OF STUDY:

The report analyzes the Fibrin Sealants market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Liquid, Patches); Application (Cardiovascular Surgery, Orthopedic Surgery, General Surgery, Transplant Surgery, Other Applications); End-Use (Hospitals, Specialty Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â